 Epizyme NASDAQ:EPZM had its target price raised by equities research analysts at Morgan Stanley from 28.00 to 31.00 in a research report issued on Friday, BenzingaRatingsTable reports. The firm presently has an overweight rating on the biopharmaceutical companys stock. Morgan Stanleys price target points to a potential upside of 64.54 from the companys current price. ... 